Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v2.4.0.6
Consolidated Statements of Operations (USD $)
In Thousands, except Share data, unless otherwise specified
 12 Months Ended 78 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Dec. 31, 2012
Operating expenses:        
Research and development $ 17,468 $ 8,583 $ 8,341 $ 42,009
General and administrative 8,665 5,755 900 16,279
In-process research and development 1,043 20,706   21,749
Loss from operations (27,176) (35,044) (9,241) (80,037)
Interest income 236 165 61 480
Interest expense (670) (74) (1,535) (3,953)
Other income     733 733
Warrant expense   (1,407)   (1,407)
Net loss (27,610) (36,360) (9,982) (84,184)
Common stock dividend to Series A Convertible Preferred stockholders    (5,861)   (5,861)
Net loss attributed to Common stockholders $ (27,610) $ (42,221) $ (9,982) $ (90,045)
Basic and diluted net loss per common share $ (1.27) $ (5.51) $ (2.24)  
Weighted average common shares outstanding-basic and diluted 21,654,984 7,662,984 4,453,786